Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Japan’s JSR Buys U.S. Biologics Maker
by Jean-François Tremblay
March 9, 2015
| A version of this story appeared in
Volume 93, Issue 10
Continuing a push into the life sciences field, Japanese chemical maker JSR will join with two partners to buy KBI Biopharma, a U.S.-based contract biopharmaceutical producer. Based in Durham, N.C., KBI offers manufacturing in mammalian-cell-based bioreactors with a capacity of up to 2,000 L. JSR, which will own the majority of KBI, says the acquisition will help it become a recognized player in the biopharmaceutical market. In recent years JSR has invested in the cell-culture and antibody purification businesses.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X